Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. In addition, it engages in the real estate operations. Cannara Biotech Inc. was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.
Frequently asked questions
What sector does Cannara Biotech Inc. (LOVE) operate in?
Cannara Biotech Inc. belongs to the Other sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Cannara Biotech Inc. (LOVE) current stock price?
As of the latest data, Cannara Biotech Inc. stock price is CA$2.02, with a previous close of CA$2.01. Cannara Biotech Inc. gained CA$0.01 in the last trading session, representing a 0.5% increase.
What is Cannara Biotech Inc. (LOVE) current market capitalization?
Cannara Biotech Inc. market cap is approximately 199.54 million.
What is Cannara Biotech Inc. (LOVE) Earnings Per Share (EPS)?
The trailing EPS is CA$0.11, and the forward EPS is CA$0.20.
What is Cannara Biotech Inc. (LOVE) Price-to-Earnings (P/E) ratio?
Cannara Biotech Inc. current P/E ratio is 18.36, with a forward P/E of 9.94.
What is Cannara Biotech Inc. (LOVE) EBITDA?
Cannara Biotech Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 3.48 million.
Does Cannara Biotech Inc. (LOVE) pay dividends?
No. Cannara Biotech Inc. does not pay a dividend.
How did Cannara Biotech Inc. (LOVE) perform in its most recent earnings report?
In the last report (May 31, 2026), Cannara Biotech Inc. posted an EPS surprise of 0% and a revenue surprise of 1.9%.
When is Cannara Biotech Inc. (LOVE) next earnings report?
Cannara Biotech Inc. is expected to release its next earnings report on August 31, 2026.
What is Cannara Biotech Inc. (LOVE) beta (volatility) score?
Cannara Biotech Inc. has a beta of 0.365, indicating lower volatility than the overall market.
